Literature DB >> 16104844

Role of resistin in obesity, insulin resistance and Type II diabetes.

Christine M Kusminski1, Philip G McTernan, Sudhesh Kumar.   

Abstract

Resistin is a member of a class of cysteine-rich proteins collectively termed resistin-like molecules. Resistin has been implicated in the pathogenesis of obesity-mediated insulin resistance and T2DM (Type II diabetes mellitus), at least in rodent models. In addition, resistin also appears to be a pro-inflammatory cytokine. Taken together, resistin, like many other adipocytokines, may possess a dual role in contributing to disease risk. However, to date there has been considerable controversy surrounding this 12.5 kDa polypeptide in understanding its physiological relevance in both human and rodent systems. Furthermore, this has led some to question whether resistin represents an important pathogenic factor in the aetiology of T2DM and cardiovascular disease. Although researchers still remain divided as to the role of resistin, this review will place available data on resistin in the context of our current knowledge of the pathogenesis of obesity-mediated diabetes, and discuss key controversies and developments.

Entities:  

Mesh:

Year:  2005        PMID: 16104844     DOI: 10.1042/CS20050078

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  79 in total

Review 1.  Oxidative stress and inflammation interactions in human obesity.

Authors:  Isabel Bondia-Pons; Lisa Ryan; J Alfredo Martinez
Journal:  J Physiol Biochem       Date:  2012-02-17       Impact factor: 4.158

Review 2.  Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity.

Authors:  Chandra Kanti Chakraborti
Journal:  World J Diabetes       Date:  2015-11-10

3.  Age-related autocrine diabetogenic effects of transgenic resistin in spontaneously hypertensive rats: gene expression profile analysis.

Authors:  Michal Pravenec; Václav Zídek; Vladimír Landa; Miroslava Simáková; Petr Mlejnek; Jan Silhavy; Martina Maxová; Ludmila Kazdová; Jonathan G Seidman; Christine E Seidman; Seda Eminaga; Joshua Gorham; Jiaming Wang; Theodore W Kurtz
Journal:  Physiol Genomics       Date:  2011-02-01       Impact factor: 3.107

Review 4.  Adipose tissue: the new endocrine organ? A review article.

Authors:  Susan E Wozniak; Laura L Gee; Mitchell S Wachtel; Eldo E Frezza
Journal:  Dig Dis Sci       Date:  2008-12-04       Impact factor: 3.199

5.  Resistin deficiency in mice has no effect on pulmonary responses induced by acute ozone exposure.

Authors:  Shehla S Razvi; Jeremy B Richards; Farhan Malik; Kevin R Cromar; Roger E Price; Cynthia S Bell; Tingting Weng; Constance L Atkins; Chantal Y Spencer; Katherine J Cockerill; Amy L Alexander; Michael R Blackburn; Joseph L Alcorn; Ikram U Haque; Richard A Johnston
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-18       Impact factor: 5.464

Review 6.  Cardiomyocyte apoptosis in animal models of obesity.

Authors:  Premal S Trivedi; Lili A Barouch
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

7.  Resistin up-regulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathway.

Authors:  Jian Zhang; Ting Lei; Xiaodong Chen; Yin Peng; Huan Long; Lei Zhou; Jianfeng Huang; Zhilong Chen; Qinqiang Long; Zaiqing Yang
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

8.  Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes.

Authors:  M Cruz; C Maldonado-Bernal; R Mondragón-Gonzalez; R Sanchez-Barrera; N H Wacher; G Carvajal-Sandoval; J Kumate
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

9.  Salicylate inhibits macrophage-secreted factors induced adipocyte inflammation and changes of adipokines in 3T3-L1 adipocytes.

Authors:  Yuan An; Kang Liu; Yuan Zhou; Baolin Liu
Journal:  Inflammation       Date:  2009-10       Impact factor: 4.092

10.  Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus.

Authors:  Sema Uslu; Nur Kebapçi; Mehmet Kara; Cengiz Bal
Journal:  Exp Ther Med       Date:  2012-04-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.